Le Lézard
Classified in: Health
Subjects: HEALTH, LIFESTYLE, MISCELLANEOUS

New curated media kits provide quick access to current thinking for journalists covering aging-related topics


Toronto, May 18, 2022 (GLOBE NEWSWIRE) -- RTOERO recently launched four new virtual media kits to help journalists covering aging-related topics. The kits, which focus on the retirement journey, insurance, ageism and healthy aging, will be updated regularly as new materials become available.

"Media and online content creators have a key role in the elimination of stereotypes and the upholding of rights for older Canadians," says Sylvia Link, director of marketing and communications for RTOERO. "As a Canadian non-profit organization focused on retirement and healthy aging, we're in a good position to support journalists in their work?to be a source of new thinking on a range of aging-related topics."

The media kits can be found in RTOERO's media centre. They each include a featured white paper and a collection of related webinars, news releases and blog articles.

Notes Link, "In our white papers, we frequently quote experts and reference research ? and so, they can be a great starting point when working on a story. We've summarized some of the current thinking on ageism, wellness across the lifespan, retirement planning and insurance?if you're looking for a new way to frame an issue, we can help you find it."

Healthy aging media kit

Featured white paper: Healthy at any age: Understanding wellness across the lifespan

Retirement journey media kit

Featured white paper: 5 ways to think about retirement planning...and money isn't one of them

Diversity, equity and inclusion with a focus on ageism

Featured white paper: The nuances of ageism: How intersectionality can impact the experience of aging

Insurance media kit

Featured white paper: The health coverage gap: How Canadian retirees can protect themselves against the inevitable

  About RTOERO

RTOERO is a bilingual trusted voice on healthy, active living in the retirement journey for the broader education community. With 82,000+ members in 51 districts across Canada, it is the largest national provider of non-profit group health benefits for education retirees.

Attachments



These press releases may also interest you

at 04:45
ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Announces International Distribution Agreement for VETIGEL with Covetrus
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
New Research by Tea Advisory Panel Reveals That Three Quarters Of Brits Never Drink Tea Before A Workout Despite It Counting Towards Fluid Intake Recommendations
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

More news about Health...


News published on and distributed by: